UCB execs take positive stance as big pharma peers wail about difficult environment
This article was originally published in Scrip
In a week in which big pharma executives Dr Marijn Dekkers of Bayer and GlaxoSmithKline's Sir Andrew Witty have drawn the limelight with their laments about the difficult environment and lack of general appreciation for the industry, executives at Belgian group UCB struck a more positive tone at their annual results meeting on Friday.
You may also be interested in...
GlamorousAI is developing technology to uncover new targets and take on previously intractable disease challenges. Founder Noor Shaker hopes to license a drug to big pharma within the next three years.
INFOGRAPHIC: In 2019, 10 blockbuster medicines booked combined sales of $92.5bn. This infographic examines those drugs that commanded the greatest revenues globally, and answers some key questions. Which therapeutic areas include the most lucrative blockbusters? Which companies enjoyed their spoils? And which drugs were new to the top 10 last year? It also takes a look at the position of these products on the all-important US market.
Fundraising in the life sciences sector has been booming even as firms in many other industries are struggling to stay in business. Goodwin’s David Mardle is upbeat about the sector’s ongoing prospects – although M&A deals are currently proving tricky to complete.